UK: A False Start For ‘Medicinal Cannabis' In The UK?

Last Updated: 6 March 2019
Article by David Hardstaff

Recently the BBC reported that despite the 'legalisation of medicinal cannabis' in November 2018, 'virtually no-one' in the UK had been able to access it since changes in the law over three months ago.

The story coincided with the news that enough cannabis to treat 30 patients for a month has arrived in the UK from the Netherlands. From this consignment, it is reported that just three patients with prescriptions, all for the treatment of chronic pain, will receive cannabis-based medicines as a result.

There was great fanfare last year when it was announced by the Home Secretary, Sajid Javid, that 'medicinal cannabis is legal.' 'Patients can be prescribed medicinal cannabis by specialist doctors from 1 November 2018', proclaimed the Government's website, as if to neutralise with one fell swoop the mounting pressure on it to respond to a small number of high-profile cases that had caught the public's attention. In addition to much work by campaigners and lobbyists, these cases signalled a sea change in public opinion and a swing towards the recognition of cannabis' therapeutic potential; and yet while many have commented on the pace of change, in practice, progress towards a fully-fledged medicinal cannabis market and regulatory framework within the UK has been slow.

Is cannabis now legal in the UK for medicinal purposes?

The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 ('2018 Regulations') came into force on 1 November 2018. Contrary to popular belief, the 2018 Regulations did not simply legalise cannabis for medicinal use. In fact, any reference to 'medicinal cannabis' within the UK's current regime is a misnomer. The 2018 Regulations included in Schedule 2 of the Misuse of Drugs Regulations 2001 ('the MDR 2001'), 'cannabis-based product for medicinal use in humans' ('CBPM'). A CBPM is defined as a 'preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which –

  1. is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);
  2. is a product for medicinal use in humans; and-
  3. is  a medicinal product, or  a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product.'

As Schedule 2 controlled drugs, CBPMs can be prescribed by specialist doctors listed on the General Medical Council's Specialist Register where there is an unmet clinical need and without requiring a Home Office licence to lawfully write a prescription.

Cannabis and cannabis-based products that do not fall within this definition remain in Schedule 1 of the MDR 2001, and thus are considered to have no therapeutic value. Controlled drugs found within Schedule 1 may only be possessed, supplied, produced, cultivated, imported or exported with a Home Office licence for research or for some other 'special purpose'.

So far so good: Medicinal cannabis, or at least CBPMs, are now Schedule 2 controlled drugs capable of being prescribed by specialist doctors. The major legal and regulatory hurdle presented by the MDR 2001 has been overcome. Furthermore, the definition of a CBPM ushered in by the 2018 Regulations is arguably broad enough to permit a wide-range of medicines. Against this backdrop, what is the explanation for the delays experienced by patients seeking access to CBPMs?

CBPM Guidelines from the National Institute for Health & Care Excellence

The National Institute for Health and Care Excellence ('NICE') is expected to publish its guidelines on prescribing CBPMs in October 2019. The guidelines will focus on sufferers of chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy. The guidelines are expected to be wide-ranging and will be aimed at healthcare professionals, providers of services for patients prescribed CBPMs and patients themselves. Until NICE publishes its guidelines, and depending on its recommendations, it is likely that few clinicians will feel suitably informed and confident to prescribe CBPMs. This is for a variety of reasons, including a lack of research into cannabis' therapeutic potential; decades of conservative drug policy in the UK; and, a former association with cannabis with only illicit use.

In addition to compliance with the NICE guidelines, CBPMs will have to fulfil the requirements of the Medicines and Healthcare products Regulatory Agency before they can be marketed and prescribed. Having just about won the PR battle and shed its 'bad boy' image, it is likely to be some time before a significant number of CBPMs are able to overcome this final and considerable hurdle. In the meantime, the medicinal cannabis market in the UK is likely to focus on research into new CBMPs and the benefits of those already available internationally.

The process through which cannabis is cultivated and compounds are extracted and isolated is also fast becoming a fertile area for research with intellectual property being recognised as likely to be more lucrative than the wholesale or retail of products themselves. The Home Office continues to act as the gatekeeper to parties interested in expanding into this field. Prospective applicants should seek early legal advice if considering applying for a controlled drug licence to undertake research in relation to cannabis. In the meantime, and while the scramble for a place in the market unfolds, the ordinary patient is likely to be left questioning what all the fuss was about.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions